文献速递淋巴瘤

奥妥珠单抗单药或联合化疗治疗初治或复发/难治慢性淋巴细胞白血病的IIIb期GREEN研究最终分析

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
PubMed 文献 · Br J Haematol · 2021-02-19

GREEN试验最终分析评估奥妥珠单抗单药或联合化疗在初治(适合与不适合强化)及复发/难治慢性淋巴细胞白血病患者中的安全性和疗效,共630例初治和341例复发/难治患者接受治疗。生物标志物分析支持特定亚组的疗效。

要点

  • 最终分析未观察到新的安全信号,安全性特征与当前风险管理策略一致。
  • 初治患者中,G-FC方案微小残留病阴性率最高;未突变IgHV患者PFS有缩短趋势。

核心结论

  • GREEN试验最终分析显示奥妥珠单抗单药或联合化疗的安全性特征与当前风险管理策略一致,未观察到新的安全信号。
  • 生物标志物分析支持奥妥珠单抗在特定亚组中的疗效。

研究设计与样本

  • IIIb期GREEN试验(NCT01905943)最终分析,数据截止2019年1月31日。
  • 共630例初治和341例复发/难治慢性淋巴细胞白血病患者接受奥妥珠单抗单药或联合化疗。
  • 主要终点为安全性,次要终点为疗效;对初治患者进行预后生物标志物亚组分析。

主要发现

  • 未突变免疫球蛋白重链患者接受奥妥珠单抗单药、联合苯达莫司汀或FC方案时,无进展生存期有缩短趋势。
  • 初治患者中,接受奥妥珠单抗联合FC方案者微小残留病阴性率最高。

临床怎么用

  • 奥妥珠单抗单药或联合化疗在初治和复发/难治慢性淋巴细胞白血病中安全性可控,可用于临床实践。
  • 治疗期间应关注中性粒细胞减少和血小板减少等血液学毒性。
  • 未突变IgHV患者可能从奥妥珠单抗联合方案中获益有限,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first-line (1L; fit and non-fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analysis of the Phase IIIb GREEN trial (Clinicaltrials.gov: NCT01905943). The final analysis (cut-off, 31 January 2019) is reported here. Patients received G (1000 mg) alone (G-mono; fit and non-fit patients) or with chemotherapy [fludarabine and cyclophosphamide (FC; fit patients); chlorambucil (non-fit patients); bendamustine (any patient)]. Study endpoints were safety (primary) and efficacy (secondary). Subgroup analyses were performed on prognostic biomarkers in 1L CLL. Overall, 630 patients received 1L and 341 received R/R CLL treatment. At the final analysis, no new safety signals were observed [Grade ≥ 3 adverse events (AEs): 1L 82·7%, R/R 84·5%; serious AEs: 1L 58·1%, R/R 62·5%]. Neutropenia (1L 50·5%, R/R 53·4%) and thrombocytopenia (1L 14·6%, R/R 19·1%) were the most common Grade 3-5 AEs. G-mono-, G-bendamustine and G-FC-treated patients with unmutated immunoglobulin heavy chain trended towards shorter progression-free survival. Achievement of minimal residual disease negativity was greatest in 1L patients treated with G-FC. In this final analysis of the GREEN trial, the safety profile of G was consistent with current risk management strategies. Biomarker analyses supported efficacy in the specific subgroups.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Stilgenbauer S, Bosch F, Ilhan O, et al. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. Br J Haematol. 2021. PMID: 33605445. doi:10.1111/bjh.17326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。